SynthesisJournal of oncology practice2015
Economics of Malignant Gliomas: A Critical Review.
Registry-linked trialOpen access · greenAbstract readMeta-Analysis
In one paragraph
Synthesis in Journal of oncology practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05425004 (A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma), which is not on this map. Cited by 35 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 6 pooled it
3.5field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma
Who cites it
35 citing papers in PubMed, 6 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Diagnostic Accuracy of Artificial Intelligence for Predicting MGMT Promoter Methylation in Glioblastoma Using MR Imaging: A Systematic Review.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026Pooled it
- Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis.Neurosurgical review · 2024Pooled it
- AI-driven estimation of O6 methylguanine-DNA-methyltransferase (MGMT) promoter methylation in glioblastoma patients: a systematic review with bias analysis.Journal of cancer research and clinical oncology · 2024Pooled it
- Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.The Cochrane database of systematic reviews · 2020Pooled it
- Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma.The Cochrane database of systematic reviews · 2019Pooled it
- Quality-adjusted life years in glioma patients: a systematic review on currently available data and the lack of evidence-based utilities.Journal of neuro-oncology · 2019Pooled it
- Protocol for neuro-oncology anywhere 242: Pilot study evaluating telehealth and in-person assessments in patients with glioma receiving oral chemotherapy.Contemporary clinical trials communications · 2026Article
- Burden of Central Nervous System Cancer in the United States, 1990-2021.JAMA neurology · 2026Article
- Differential Effects of Extracellular Vesicles from Two Different Glioblastomas on Normal Human Brain Cells.Neurology international · 2024Article
- Telehealth Utilization in Neuro-Oncology: Commentary on a Single Institution Experience After the COVID-19 Pandemic.Current oncology reports · 2024Review
- Healthcare spending versus mortality in central nervous system cancer: Has anything changed?Neuro-oncology practice · 2024Article
- Pharmaceutical equivalent 5-aminolevulinic acid fluorescence guided resection of central nervous system tumors: feasibility, safeness and cost-benefit considerations.Journal of neuro-oncology · 2024Article
- Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess.Frontiers in pharmacology · 2024Article
- Association between viral infections and glioma risk: a two-sample bidirectional Mendelian randomization analysis.BMC medicine · 2023Article
- Association of Employment Status With Symptom Burden and Health-Related Quality of Life in People Living With Primary CNS Tumors.Neurology · 2023Observational
- Global Landscape of Glioblastoma Multiforme Management in the Stupp Protocol Era: Systematic Review Protocol.International journal of surgery protocols · 2021Article
- A Position Statement on the Utility of Interval Imaging in Standard of Care Brain Tumour Management: Defining the Evidence Gap and Opportunities for Future Research.Frontiers in oncology · 2021Review
- Radiotherapy for glioblastoma in the elderly: A protocol for systematic review and meta-analysis.Medicine · 2020Article
- Multiparameter quantitative histological MRI values in high-grade gliomas: a potential biomarker of tumor progression.Neuro-oncology practice · 2020Article
- Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study.Neuro-oncology practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Jeffrey J RaizerNorthwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Northwestern University; DePaul University; Rush Medical College; Northwestern Memorial Hospital; University of Chicago, Chicago; Midwestern University, Downers Grove; Northshore University Health Systems, Skokie Hospital, Skokie, IL; Yale School of Public Health, New Haven, CT; and South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, the University of South Carolina, Columbia, SC.
Karen A FitznerNorthwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Northwestern University; DePaul University; Rush Medical College; Northwestern Memorial Hospital; University of Chicago, Chicago; Midwestern University, Downers Grove; Northshore University Health Systems, Skokie Hospital, Skokie, IL; Yale School of Public Health, New Haven, CT; and South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, the University of South Carolina, Columbia, SC.
Daniel I JacobsNorthwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Northwestern University; DePaul University; Rush Medical College; Northwestern Memorial Hospital; University of Chicago, Chicago; Midwestern University, Downers Grove; Northshore University Health Systems, Skokie Hospital, Skokie, IL; Yale School of Public Health, New Haven, CT; and South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, the University of South Carolina, Columbia, SC.
Charles L BennettNorthwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Northwestern University; DePaul University; Rush Medical College; Northwestern Memorial Hospital; University of Chicago, Chicago; Midwestern University, Downers Grove; Northshore University Health Systems, Skokie Hospital, Skokie, IL; Yale School of Public Health, New Haven, CT; and South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, the University of South Carolina, Columbia, SC.
Dustin B LieblingNorthwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Northwestern University; DePaul University; Rush Medical College; Northwestern Memorial Hospital; University of Chicago, Chicago; Midwestern University, Downers Grove; Northshore University Health Systems, Skokie Hospital, Skokie, IL; Yale School of Public Health, New Haven, CT; and South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, the University of South Carolina, Columbia, SC.
Thanh Ha LuuNorthwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Northwestern University; DePaul University; Rush Medical College; Northwestern Memorial Hospital; University of Chicago, Chicago; Midwestern University, Downers Grove; Northshore University Health Systems, Skokie Hospital, Skokie, IL; Yale School of Public Health, New Haven, CT; and South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, the University of South Carolina, Columbia, SC.
Steven M TrifilioNorthwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Northwestern University; DePaul University; Rush Medical College; Northwestern Memorial Hospital; University of Chicago, Chicago; Midwestern University, Downers Grove; Northshore University Health Systems, Skokie Hospital, Skokie, IL; Yale School of Public Health, New Haven, CT; and South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, the University of South Carolina, Columbia, SC.
Sean A GrimmNorthwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Northwestern University; DePaul University; Rush Medical College; Northwestern Memorial Hospital; University of Chicago, Chicago; Midwestern University, Downers Grove; Northshore University Health Systems, Skokie Hospital, Skokie, IL; Yale School of Public Health, New Haven, CT; and South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, the University of South Carolina, Columbia, SC.
Matthew J FisherNorthwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Northwestern University; DePaul University; Rush Medical College; Northwestern Memorial Hospital; University of Chicago, Chicago; Midwestern University, Downers Grove; Northshore University Health Systems, Skokie Hospital, Skokie, IL; Yale School of Public Health, New Haven, CT; and South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, the University of South Carolina, Columbia, SC.
Meraaj S HaleemNorthwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Northwestern University; DePaul University; Rush Medical College; Northwestern Memorial Hospital; University of Chicago, Chicago; Midwestern University, Downers Grove; Northshore University Health Systems, Skokie Hospital, Skokie, IL; Yale School of Public Health, New Haven, CT; and South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, the University of South Carolina, Columbia, SC.
Paul S RayNorthwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Northwestern University; DePaul University; Rush Medical College; Northwestern Memorial Hospital; University of Chicago, Chicago; Midwestern University, Downers Grove; Northshore University Health Systems, Skokie Hospital, Skokie, IL; Yale School of Public Health, New Haven, CT; and South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, the University of South Carolina, Columbia, SC.
Judith M McKoyNorthwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Northwestern University; DePaul University; Rush Medical College; Northwestern Memorial Hospital; University of Chicago, Chicago; Midwestern University, Downers Grove; Northshore University Health Systems, Skokie Hospital, Skokie, IL; Yale School of Public Health, New Haven, CT; and South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, the University of South Carolina, Columbia, SC.
Rebecca DeBoerNorthwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Northwestern University; DePaul University; Rush Medical College; Northwestern Memorial Hospital; University of Chicago, Chicago; Midwestern University, Downers Grove; Northshore University Health Systems, Skokie Hospital, Skokie, IL; Yale School of Public Health, New Haven, CT; and South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, the University of South Carolina, Columbia, SC.
Katrina-Marie E TulasNorthwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Northwestern University; DePaul University; Rush Medical College; Northwestern Memorial Hospital; University of Chicago, Chicago; Midwestern University, Downers Grove; Northshore University Health Systems, Skokie Hospital, Skokie, IL; Yale School of Public Health, New Haven, CT; and South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, the University of South Carolina, Columbia, SC.
Mohammed DeebNorthwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Northwestern University; DePaul University; Rush Medical College; Northwestern Memorial Hospital; University of Chicago, Chicago; Midwestern University, Downers Grove; Northshore University Health Systems, Skokie Hospital, Skokie, IL; Yale School of Public Health, New Haven, CT; and South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, the University of South Carolina, Columbia, SC.
June M McKoyNorthwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Northwestern University; DePaul University; Rush Medical College; Northwestern Memorial Hospital; University of Chicago, Chicago; Midwestern University, Downers Grove; Northshore University Health Systems, Skokie Hospital, Skokie, IL; Yale School of Public Health, New Haven, CT; and South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, the University of South Carolina, Columbia, SC j-mckoy@northwestern.edu.
Northwestern Memorial Hospital · US
Funding
Adverse Drug Reactions in Geriatric Cancer PatientsK01CA134554 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCKOY, JUNE M. · 2008 to 2012
$737kNCI NIH HHS K01 CA134554
Abstract
purposeApproximately 18,500 persons are diagnosed with malignant glioma in the United States annually. Few studies have investigated the comprehensive economic costs. We reviewed the literature to examine costs to patients with malignant glioma and their families, payers, and society.
methodsA total of 18 fully extracted studies were included. Data were collected on direct and indirect costs, and cost estimates were converted to US dollars using the conversion rate calculated from the study's publication date, and updated to 2011 values after adjustment for inflation. A standardized data abstraction form was used. Data were extracted by one reviewer and checked by another.
resultsBefore approval of effective chemotherapeutic agents for malignant gliomas, estimated total direct medical costs in the United States for surgery and radiation therapy per patient ranged from $50,600 to $92,700. The addition of temozolomide (TMZ) and bevacizumab to glioblastoma treatment regimens has resulted in increased overall costs for glioma care. Although health care costs are now less front-loaded, they have increased over the course of illness. Analysis using a willingness-to-pay threshold of $50,000 per quality-adjusted life-year suggests that the benefits of TMZ fall on the edge of acceptable therapies. Furthermore, indirect medical costs, such as productivity losses, are not trivial.
conclusionWith increased chemotherapy use for malignant glioma, the paradigm for treatment and associated out-of-pocket and total medical costs continue to evolve. Larger out-of-pocket costs may influence the choice of chemotherapeutic agents, the economic implications of which should be evaluated prospectively.
Indexed as
Brain NeoplasmsCanadaCost of IllnessCosts and Cost AnalysisDacarbazineDrug TherapyEuropeGliomaHumansRadiotherapyTemozolomideUnited StatesDacarbazineTemozolomide
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT05425004ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.